Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance

Cancer Prevention Research

Volumn 7, Issue 8, 2014, Pages 805-812

  Guda, Kishore ^a   Fink, Stephen P ^a   Milne, Ginger L ^c   Molyneaux, Neil ^a   Ravi, Lakshmeswari ^a   Lewis, Susan M ^a   Dannenberg, Andrew J ^e   Montgomery, Courtney G ^f   Zhang, Shulin ^a   Willis, Joseph ^a,b   Wiesner, Georgia L ^d   Markowitz, Sanford D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN TRANSPORTER; SULINDAC; ORGANIC ANION TRANSPORTER; PROSTAGLANDIN; SLCO2A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CATABOLISM; COLON ADENOMA; COLON CANCER; COLON TUMOR; DIGITAL CLUBBING; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GENE SEGREGATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MALE; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; VERY ELDERLY; ALGORITHM; ALLELE; DNA SEQUENCE; EXOME; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; OSTEOARTHROPATHY; PEDIGREE; URINE;

ADULT; ALGORITHMS; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; DINOPROSTONE; DRUG RESISTANCE; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANIC ANION TRANSPORTERS; OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC; PEDIGREE; PHENOTYPE; PROSTAGLANDINS; SEQUENCE ANALYSIS, DNA;

EID: 84905826523     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0108     Document Type: Article

References (50)

1. Sarkar M, Mahesh DM, Madabhavi I. Digital clubbing. Lung India 2012;29:354-62.
2. Castori M, Sinibaldi L, Mingarelli R, Lachman RS, Rimoin DL, Dallapiccola B. Pachydermoperiostosis: an update. Clin Genet 2005;68:477-86. (Pubitemid 41748846)
3. Gomez Rodriguez N, Ibanez Ruan J, Gonzalez Perez M. Primary hypertrophic osteoarthropathy (pachydermoperiostosis). Report of two familial cases and literature review. Reumatol Clin 2009;5:259-63.
4. Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008;40:789-93. (Pubitemid 351748871)
5. Yuksel-Konuk B, Sirmaci A, Ayten GE, Ozdemir M, Aslan I, Yilmaz-Turay U, et al. Homozygous mutations in the 15-hydroxyprostaglandin dehydrogenase gene in patients with primary hypertrophic osteoarthropathy. Rheumatol Int 2009;30:39-43.
6. Diggle CP, Carr IM, Zitt E, Wusik K, Hopkin RJ, Prada CE, et al. Common and recurrent HPGD mutations in Caucasian individuals with primary hypertrophic osteoarthropathy. Rheumatology 2010;49:1056-62.
7. Sinibaldi L, Harifi G, Bottillo I, Iannicelli M, El Hassani S, Brancati F, et al. A novel homozygous splice site mutation in the HPGD gene causes mild primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 2010;28:153-7.
8. Bergmann C, Wobser M, Morbach H, Falkenbach A, Wittenhagen D, Lassay L, et al. Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol 2011;20:531-3.
9. Busch J, Frank V, Bachmann N, Otsuka A, Oji V, Metze D, et al. Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing. J Invest Dermatol 2012;132:2473-6.
10. Diggle CP, Parry DA, Logan CV, Laissue P, Rivera C, Restrepo CM, et al. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat 2012;33:1175-81.
11. Sasaki T, Niizeki H, Shimizu A, Shiohama A, Hirakiyama A, Okuyama T, et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci 2012;68:36-44.
12. Seifert W, Kuhnisch J, Tuysuz B, Specker C, Brouwers A, Horn D. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat 2012;33:660-4.
13. Erken E, Koroglu C, Yildiz F, Ozer HT, Gulek B, Tolun A. A novel recessive 15-hydroxyprostaglandin dehydrogenase mutation in a family with primary hypertrophic osteoarthropathy. Mod Rheumatol 2014 Feb 18. [Epub ahead of print].
14. Zhang Z, He JW, Fu WZ, Zhang CQ, Zhang ZL. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab 2013;98:E923-33.
15. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res 2008;1:93-9.
16. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL. Identification and characterization of a prostaglandin transporter. Science 1995;268:866-9.
17. Markowitz SD. Colorectal neoplasia goes with the flow: prostaglandin transport and termination. Cancer Prev Res 2008;1:77-9.
18. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28-32. (Pubitemid 34073980)
19. Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004;65:973-8. (Pubitemid 38420503)
20. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6. (Pubitemid 38050040)
21. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001;108:1657-65. (Pubitemid 33144876)
22. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
23. Menter DG, Dubois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012;2012:723419.
24. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 2013;35:123-37.
25. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23. (Pubitemid 40223783)
26. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-102. (Pubitemid 44215817)
27. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-13.
28. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-73. (Pubitemid 39657428)
29. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2012;5:164-78.
30. Arber N, Spicak J, Racz I, Zavoral M, Breazna A, Gerletti P, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46.
31. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
32. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets down-stream of COX-2. Annu Rev Med 2007;58:239-52. (Pubitemid 46706512)
33. Wiesner GL, Daley D, Lewis S, Ticknor C, Platzer P, Lutterbaugh J, et al. A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31.2. Proc Natl Acad Sci U S A 2003;100:12961-5. (Pubitemid 37340008)
34. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
35. Li R, Li Y, Fang X, Yang H, Wang J, Kristiansen K. SNP detection for massively parallel whole-genome resequencing. Genome Res 2009;19:1124-32.
36. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-9.
38. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclo-oxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75. (Pubitemid 39370961)
39. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res 2013;6:428-36.
40. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 2002;282:F1103-10. (Pubitemid 34654476)
41. Schuster VL. Prostaglandin transport. Prostaglandins Other Lipid Mediat 2002;68-69:633-47. (Pubitemid 35247426)
42. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite and leukotriene E (4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2:322-9.
43. Ferretti A, Flanagan VP, Roman JM. Quantitative analysis of 11 alpha-hydroxy-9, 15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid, the major urinary metabolite of E prostaglandins in man. Anal Biochem 1983;128:351-8. (Pubitemid 13132641)
44. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-93. (Pubitemid 41170341)
45. Seyberth HW, Sweetman BJ, Frolich JC, Oates JA. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976;11:381-97.
46. Wang D, DuBois RN. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J 2013;19:502-10.
47. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42. (Pubitemid 47010839)
48. Diaz-Munoz MD, Osma-Garcia IC, Fresno M, Iniguez MA. Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. Biochem J 2012;443:451-61.
49. Crockett SD, Snover DC, Ahnen DJ, Baron JA. Sessile Serrated Adenomas: An Evidence-Based Guide to Management. Clin Gastroenterol Hepatol 2013 Nov 19. [Epub ahead of print].
50. Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev 2009;18:2310-7.